SecSonar.com

Novavax, Inc. (NVAX)

Novavax, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Novavax, Inc. (NVAX) is a Biotechnology company based in US with a market capitalization of $1.8B. Revenue grew 64.7% year-over-year and free cash flow was negative at -$250.2M. This page tracks NVAX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 952 employees · IPO Dec 5, 1995

Valuation

Valuation & price

$9.06 · as of May 17, 2026 · -19.0% vs 52w high

3.6

P/E ratio

Latest-FY diluted EPS

—

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$11.19$8.71$6.22Jul 25Dec 25Jul 26Jul 7, 25$6.61Jul 9, 25$7.04Jul 11, 25$6.84Jul 15, 25$6.88Jul 17, 25$7.00Jul 21, 25$7.17Jul 23, 25$7.84Jul 25, 25$7.47Jul 29, 25$7.01Jul 31, 25$6.65Aug 4, 25$6.75Aug 6, 25$7.58Aug 11, 25$8.03Aug 13, 25$8.85Aug 15, 25$9.58Aug 19, 25$9.52Aug 21, 25$7.63Aug 25, 25$7.52Aug 27, 25$7.58Aug 29, 25$7.47Sep 3, 25$7.40Sep 5, 25$7.90Sep 9, 25$7.96Sep 11, 25$8.28Sep 16, 25$8.56Sep 18, 25$8.53Sep 22, 25$8.87Sep 24, 25$8.64Sep 26, 25$8.55Sep 30, 25$8.67Oct 2, 25$9.55Oct 6, 25$9.08Oct 8, 25$8.90Oct 10, 25$8.33Oct 14, 25$8.89Oct 16, 25$8.48Oct 21, 25$8.59Oct 23, 25$8.36Oct 27, 25$8.70Oct 29, 25$8.38Oct 31, 25$8.40Nov 4, 25$7.51Nov 6, 25$7.59Nov 10, 25$7.11Nov 12, 25$7.20Nov 14, 25$6.97Nov 18, 25$6.57Nov 20, 25$6.22Nov 25, 25$6.69Nov 28, 25$7.05Dec 2, 25$6.60Dec 4, 25$6.86Dec 8, 25$6.78Dec 10, 25$6.74Dec 12, 25$6.57Dec 16, 25$6.54Dec 18, 25$6.68Dec 22, 25$6.89Dec 24, 25$6.94Dec 29, 25$6.82Jan 2, 26$7.13Jan 6, 26$7.44Jan 8, 26$7.34Jan 12, 26$7.75Jan 14, 26$8.19Jan 16, 26$8.01Jan 21, 26$9.90Jan 23, 26$9.17Jan 27, 26$9.82Jan 29, 26$9.44Feb 2, 26$8.69Feb 4, 26$8.27Feb 9, 26$8.70Feb 11, 26$8.97Feb 13, 26$8.70Feb 18, 26$8.69Feb 20, 26$9.20Feb 24, 26$9.46Feb 26, 26$11.19Mar 2, 26$10.11Mar 4, 26$9.89Mar 6, 26$9.98Mar 10, 26$10.69Mar 12, 26$10.30Mar 17, 26$10.64Mar 19, 26$9.74Mar 23, 26$9.72Mar 25, 26$9.34Mar 27, 26$8.45Mar 31, 26$8.14Apr 2, 26$7.70Apr 7, 26$7.98Apr 9, 26$8.54Apr 13, 26$8.11Apr 15, 26$8.69Apr 17, 26$8.84Apr 22, 26$8.45Apr 24, 26$8.22Apr 28, 26$7.92Apr 30, 26$7.93May 4, 26$8.03May 6, 26$9.36May 8, 26$10.11May 12, 26$9.62May 14, 26$9.35May 18, 26$8.93May 20, 26$9.27May 22, 26$9.21May 28, 26$10.32Jun 1, 26$10.51Jun 3, 26$10.20Jun 5, 26$9.49Jun 9, 26$8.67Jun 11, 26$9.03Jun 15, 26$9.21Jun 17, 26$9.50Jun 22, 26$9.00Jun 24, 26$8.90Jun 26, 26$8.88Jul 2, 26$9.74
$6.2252-week range$11.19
Loading valuation history…

Fundamentals

Key fundamentals

$1.8B

Market cap

64.7%

Revenue growth (YoY)

93.7%

Gross margin

-$250.2M

Free cash flow (USD)

-$486.3M

Net debt

Net cash position

6.4%

Share dilution

1/4

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$15.4MFY 2017$31.2MFY 2018$34.3MFY 2019$18.7MFY 2020$22.4MFY 2021$197.6MFY 2022$1.6BFY 2023$556.4MFY 2024$682.2MFY 2025$1.1B
$15.4M$1.1B

Free cash flow by year

2016 → 2025

FY 2016$-273.7MFY 2017$-142.9MFY 2018$-186.2MFY 2019$-138.5MFY 2020$-97.2MFY 2021$265.5MFY 2022$-508.9MFY 2023$-772.8MFY 2024$-100.3MFY 2025$-250.2M
-$273.7M-$250.2M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 202243.5%FY 202338.2%FY 202470.3%FY 202593.7%
100.0%93.7%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 6, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsJun 23, 2026Filing
  • Quarterly report10-Q FiledMay 6, 2026Filing
  • 8-K eventEarnings ReleaseMay 6, 2026Filing

Questions

Frequently asked questions

What is Novavax, Inc.'s market cap?

Novavax, Inc. (NVAX) has a market capitalization of $1.8B.

What is NVAX's P/E ratio?

NVAX trades at a price-to-earnings ratio of 3.6, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

Are insiders buying NVAX stock?

SEC Form 4 filings show no open-market insider buys at Novavax, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

HRMY

Harmony Biosciences Holdings, Inc.

$1.8B

AGIO

Agios Pharmaceuticals, Inc.

$1.8B

ZYME

Zymeworks Inc.

$1.9B

AAPG

Ascentage Pharma Group International

$1.9B

BCRX

BioCryst Pharmaceuticals, Inc.

$1.9B

SNDX

Syndax Pharmaceuticals, Inc.

$1.7B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.